ACE Inhibitors Boost Mobility and Muscle Strength by Reducing Intestinal Permeability in Older Adults with Alzheimer’s Disease

<b>Objectives:</b> Hypertension is common in Alzheimer's disease (AD) and contributes to functional decline. While ACE inhibitors are widely used for hypertension, their systemic effects on intestinal permeability and physical capacity in AD patients remain unclear. <b>Materials and Methods:</b> We investigated the potential contribution of increased intestinal permeability to handgrip strength (HGS) and physical capacity in patients with Alzheimer's disease (AD) taking ACE inhibitors. We investigated hypertensive AD patients taking ACE inhibitors (<i>n</i> = 55) or other anti-hypertensive medications (<i>n</i> = 57) at baseline and one year later, along with age-matched controls (<i>n</i> = 64) and normotensive AD patients (<i>n</i> = 61). We measured plasma zonulin, a marker of intestinal permeability, and HGS, and performed the short physical performance battery (SPPB). <b>Results:</b> AD patients had lower HGS, gait speed, SPPB, and higher plasma zonulin than controls at baseline (all <i>p</i> < 0.05). The use of ACE inhibitors was associated with increased HGS and gait speed, and reduced plasma zonulin in AD patients. Conversely, AD patients on other anti-hypertensive medications had higher zonulin and lower HGS but no change in gait speed and SPPB after one year. The patients taking ACE inhibitors also exhibited significant dynamic correlations of zonulin with HGS, gait speed, and SPPB (<i>p</i> < 0.05). ACE inhibitors also reduced plasma C-reactive proteins and 8-isoprostanes as markers of oxidative stress and inflammation. <b>Conclusions:</b> ACE inhibitors may improve physical performance and cognitive function in hypertensive AD patients, primarily through vascular smooth muscle modulation, leading to better perfusion. These effects may indirectly support intestinal barrier and muscle function, highlighting a novel gut-vascular-muscle interface relevant to therapeutic strategies.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-02-12
DOI
https://doi.org/10.3390/ph19020304
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ACE Inhibitors Boost Mobility and Muscle Strength by Reducing Intestinal Permeability in Older Adults with Alzheimer’s Disease

Khalid Saeed, Shaea Ayed Alkahtani, Asima Karim, Rizwan Qaisar et al.
Pharmaceuticals
Alzheimer's disease research and treatments
article

ACE Inhibitors Boost Mobility and Muscle Strength by Reducing Intestinal Permeability in Older Adults with Alzheimer’s Disease

Khalid Saeed, Shaea Ayed Alkahtani, Asima Karim, Rizwan Qaisar, M. Shahid Iqbal, Firdos Ahmad
article en

Abstract

<b>Objectives:</b> Hypertension is common in Alzheimer's disease (AD) and contributes to functional decline. While ACE inhibitors are widely used for hypertension, their systemic effects on intestinal permeability and physical capacity in AD patients remain unclear. <b>Materials and Methods:</b> We investigated the potential contribution of increased intestinal permeability to handgrip strength (HGS) and physical capacity in patients with Alzheimer's disease (AD) taking ACE inhibitors. We investigated hypertensive AD patients taking ACE inhibitors (<i>n</i> = 55) or other anti-hypertensive medications (<i>n</i> = 57) at baseline and one year later, along with age-matched controls (<i>n</i> = 64) and normotensive AD patients (<i>n</i> = 61). We measured plasma zonulin, a marker of intestinal permeability, and HGS, and performed the short physical performance battery (SPPB). <b>Results:</b> AD patients had lower HGS, gait speed, SPPB, and higher plasma zonulin than controls at baseline (all <i>p</i> < 0.05). The use of ACE inhibitors was associated with increased HGS and gait speed, and reduced plasma zonulin in AD patients. Conversely, AD patients on other anti-hypertensive medications had higher zonulin and lower HGS but no change in gait speed and SPPB after one year. The patients taking ACE inhibitors also exhibited significant dynamic correlations of zonulin with HGS, gait speed, and SPPB (<i>p</i> < 0.05). ACE inhibitors also reduced plasma C-reactive proteins and 8-isoprostanes as markers of oxidative stress and inflammation. <b>Conclusions:</b> ACE inhibitors may improve physical performance and cognitive function in hypertensive AD patients, primarily through vascular smooth muscle modulation, leading to better perfusion. These effects may indirectly support intestinal barrier and muscle function, highlighting a novel gut-vascular-muscle interface relevant to therapeutic strategies.

PharmaceuticalsVol. 19(2)
University of Helsinki (FI), Khyber Medical College (PK), King Saud University (SA), University of Sharjah (AE)
Good health and well-being
Openalex Percentile: Top 56%
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.